Cancer care in Switzerland
Switzerland is known for having one of the best healthcare systems in the world. The decentralised structure favours an almost unconstrained choice of providers and a high availability and accessibility of healthcare services. However, this comes at a significant cost: health expenditure in Switzerland is higher than in most Organisation for Economic Co-operation and Development (OECD) countries. This is why international organisations like the World Health Organization and OECD have pointed out that Switzerland’s main challenges lie in becoming more cost-effective.1 Indeed, with the second highest healthcare spending in the world2 and an above-average investment in cancer care of more than 6%,3 Switzerland produces lower health outcomes per money spent compared with other countries.4
Every year, more than 40,000 Swiss citizens are diagnosed with cancer.5 While incidence rates for cancer have remained constant since 1980, mortality rates have dropped by more than 30%. This achievement was possible thanks to medical advances in diagnostic technology, medicines and care.6 Nonetheless, the diagnosis for people with cancer still comes with a high burden for patients as well as their environment. There are countless opportunities across Switzerland to make cancer care more efficient and more sustainable. In particular, cancer care should become more patient-centred, focusing on patient needs and patient-reported outcomes. This is what All.Can Switzerland intends to do.
All.Can Switzerland initiative
All.Can Switzerland launched in early 2018 with a handful of interested stakeholders. Throughout the year, its first projects were initiated. In November 2019, All.Can Switzerland officially launched as a Non-profit organisation with an event at the University of Zurich with nearly 100 stakeholders of the Swiss healthcare and policy system present.
All.Can Switzerland’s vision is to develop solutions for sustainable cancer care, with a strong focus on improving patient outcomes. All.Can Switzerland wants to achieve this through an open dialogue and a broad collaboration with all interested stakeholders sharing the same vision.
Therefore, we are continuously expanding our membership base and are always looking for interested stakeholders and possible project partners. Interested in All.Can Switzerland? Please get in touch with us: email@example.com
- OECD. 2011. OECD Reviews of Health Systems – Switzerland, p. 9. Available here: http://www.oecd.org/switzerland/oecdreviewsofhealthsystems-switzerland.htm [accessed: May 2018]
- OECD. 2018. Health spending. Available here: https://data.oecd.org/chart/5b8O [accessed: May 2018]
- Wieser et al. 2014. Die Kosten der nichtübertragbaren Krankheiten in der Schweiz, Schlussbericht, p. 52. Available here: http://bit.ly/zhaw14 [accessed: August 2018]
- OECD. 2018 Available here: http://stats.oecd.org/ [accessed: May 2018]
- Heusser et al. 2017. Krebs in der Schweiz, Zahlen Weiterentwicklung der Krebsregistrierung und Folgen, in: Onkologe, 23:588-596. Available here: http://dx.doi.org/10.1007/s00761-017-0252-4
- Federal Office of Statistics/NICER. 2017. Schweizer Krebsbericht 2015. Available here: http://bit.ly/Krebsbericht [accessed: August 2018]
Professor Brigitte Tag
Dean, Faculty of Law, Chair for Criminal and Medical Law, University of Zurich
Lucerne University of Applied Sciences and Arts, Competence Center for Public and Nonprofit Management
Professor Bettina Borisch, MD, MPH, FRCPath
Institute of Global Health, University of Geneva
Bristol Myers Squibb
General Manager, Amgen
Managing Director MSD Switzerland
University of Zurich, Competence Center for Medical Ethics and Law Helvetiae
Value, Access & Policy Manager, Amgen
Bristol Myers Squibb
All.Can Switzerland initiative officially launches as a non-profit organisation
All.Can Switzerland has officially launched as a non-profit organisation with an event at the University of Zurich.
Switzerland becomes latest country to launch national All.Can initiative
All.Can Switzerland has officially launched, joining other countries across Europe, Australia and Canada.
All.Can Switzerland steering committee meeting – 23 Jan 2019
23 January 2019
All.Can Switzerland steering committee meeting – 20 Mar 2019
20 March 2019
All.Can Switzerland steering committee meeting – 28 May 2019
28 May 2019
All.Can Switzerland steering committee meeting – 9 July 2019
9 July 2019
All.Can Switzerland steering committee meeting – 23 Sept 2019
23 September 2019
All.Can Switzerland steering committee meeting – 12 Nov 2019
12 November 2019
All.Can Switzerland steering committee meeting – 31 Jan 2020
31 January 2020
All.Can Switzerland steering committee meeting – 12 May 2020
12 May 2020
All.Can Switzerland board meeting – 1 July 2020
1 July 2020
All.Can Switzerland steering committee meeting – 23 Aug 2020
25 August 2020
All.Can Switzerland steering committee meeting – 17 Nov 2020
17 November 2020
All.Can Switzerland an introduction
Interview with Isabel Baur
Isabel Baur, University of Zurich, Competence Center for Medical Ethics and Law Helvetiae, talks about the ‘fresh ideas for cancer care’ project, which unites PhD students with stakeholders from various sectors to develop innovations in cancer care.
Interview with Oliver Kessler
Oliver Kessler, Lucerne University of Applied Sciences and Arts, Competence Center for Public and Nonprofit Management, talks about the All.Can Switzerland project focusing on optimising cancer care in central Switzerland.
The All.Can initiative is made up of leading representatives of patient organisations, policymakers, healthcare professionals, science and industry. All the publications produced under the initiative reflect the consensus of All.Can members who have full editorial control. The All.Can initiative in Switzerland is supported (financially and/or in kind) by Amgen, Bristol-Myers Squibb, MSD, Lucerne University of Applied Sciences and Arts, and University of Zurich.